The goal of the UNC CFAR Immunology Core is to support HIV research by UNC and affiliated investigators aimed at stemming the HIV pandemic. The Immunology Core will achieve this goal by providing infrastructure, services and leadership to facilitate studies ofthe Immunologic aspects of HIV pathogenesis, therapeutics and diagnostics. Specifically, the Core will provide services including: biospecimen procurement and distribution, flow cytometry, immune function testing, soluble marker testing, mmunogenetic testing and training/education. The Core will promote the use of these services by supporting developmental awardees, assisting with the development of grants and contracts addressing immunologic questions of HIV infection and fostering collaborations with industry for evaluation of novel technologies for the diagnosis and monitoring of HIV infection. The Core's established services as well as methods and tools developed via support of investigators and industry will also be used to support various DAIDS groups (ACTG, HPTN, CHAVI), to build capacity at international sites and to support UNC CFAR initiatives including HIV latency, primary infection and AIDS malignancies. Finally, the Core will actively seek input from these users as well as other internal and external advisors to continually assess and improve Core services. By supporting a broad research agenda including pathogenesis, therapeutics and diagnostics, the Core will be a significant component of the efforts to address the HIV pandemic.
The Immunology Core research plan will impact public health in several ways. The core will provide infrastructure and resources to support studies aimed at: (1) preventing transmission of HIV;(2) improving the diagnosis and monitoring of infected persons;(3) elucidating mechanisms of HIV disease, and;(4) improving therapies for HIV infected persons.
|Cottrell, Mackenzie L; Yang, Kuo H; Prince, Heather M A et al. (2016) A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine. J Infect Dis 214:55-64|
|Sin, Sang-Hoon; Kang, Sun Ah; Kim, Yongbaek et al. (2016) Kaposi's Sarcoma-Associated Herpesvirus Latency Locus Compensates for Interleukin-6 in Initial B Cell Activation. J Virol 90:2150-4|
|Rutstein, S E; Golin, C E; Wheeler, S B et al. (2016) On the front line of HIV virological monitoring: barriers and facilitators from a provider perspective in resource-limited settings. AIDS Care 28:1-10|
|Davis, Nicole L; Miller, William C; Hudgens, Michael G et al. (2016) Maternal and Breastmilk Viral Load: Impacts of Adherence on Peripartum HIV Infections Averted-The Breastfeeding, Antiretrovirals, and Nutrition Study. J Acquir Immune Defic Syndr 73:572-580|
|Davis, Alissa; Meyerson, Beth E; Aghaulor, Blessing et al. (2016) Barriers to health service access among female migrant Ugandan sex workers in Guangzhou, China. Int J Equity Health 15:170|
|Chen, J; Malone, S; Prince, H M A et al. (2016) Model-Based Analysis of Unbound Lopinavir Pharmacokinetics in HIV-Infected Pregnant Women Supports Standard Dosing in the Third Trimester. CPT Pharmacometrics Syst Pharmacol 5:147-57|
|Cottrell, Mackenzie L; Prince, Heather M A; Allmon, Andrew et al. (2016) Cervicovaginal and Rectal Fluid as a Surrogate Marker of Antiretroviral Tissue Concentration: Implications for Clinical Trial Design. J Acquir Immune Defic Syndr 72:498-506|
|Lancaster, Kathryn E; Go, Vivian F; Lungu, Thandie et al. (2016) Substance use and HIV infection awareness among HIV-infected female sex workers in Lilongwe, Malawi. Int J Drug Policy 30:124-31|
|O'Donnell, Julie K; Gaynes, Bradley N; Cole, Stephen R et al. (2016) Ongoing life stressors and suicidal ideation among HIV-infected adults with depression. J Affect Disord 190:322-8|
|Barlow-Mosha, Linda; Angelidou, Konstantia; Lindsey, Jane et al. (2016) Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial. Clin Infect Dis 63:1113-21|
Showing the most recent 10 out of 1330 publications